Salvage Second Hematopoietic Cell Transplantation in Myeloma

Laura C. Michaelis, Ayman Saad, Xiaobo Zhong, Jennifer Le-Rademacher, Cesar O. Freytes, David I. Marks, Hillard M. Lazarus, Jennifer M. Bird, Leona Holmberg, Rammurti T. Kamble, Shaji Kumar, Michael Lill, Kenneth R. Meehan, Wael Saber, Jeffrey Schriber, Jason Tay, Dan T. Vogl, Baldeep Wirk, Bipin N. Savani, Robert P. Gale & 29 others David H. Vesole, Gary J. Schiller, Muneer Abidi, Kenneth C. Anderson, Taiga Nishihori, Matt E. Kalaycio, Julie M. Vose, Jan S. Moreb, William Drobyski, Reinhold Munker, Vivek Roy, Armin Ghobadi, H. Kent Holland, Rajneesh Nath, L. Bik To, Angelo Maiolino, Adetola A. Kassim, Sergio A. Giralt, Heather Landau, Harry C. Schouten, Richard Maziarz, Joseph Michael, Tamila Kindwall-Keller, Patrick J. Stiff, John Gibson, Sagar Lonial, Amrita Krishnan, Angela Dispenzieri, Parameswaran Hari

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with multiple myeloma (MM) improves survival. However, data to support this approach for relapsed/progressive disease after initial AHCT (AHCT1) are limited. Using Center for International Blood and Marrow Transplant Research data, we report the outcomes of 187 patients who underwent a second AHCT (AHCT2) for the treatment of relapsed/progressive MM. Planned tandem AHCT was excluded. Median age at AHCT2 was 59 years (range, 28 to 72), and median patient follow-up was 47 months (range, 3 to 97). Nonrelapse mortality after AHCT2 was 2% at 1 year and 4% at 3 years. Median interval from AHCT1 to relapse/progression was 18 months, and median interval between transplantations was 32 months. After AHCT2, the incidence of relapse/progression at 1 and 3 years was 51% and 82%, respectively. At 3 years after AHCT2, progression-free survival was 13%, and overall survival was 46%. In multivariate analyses, those relapsing ≥36 months after AHCT1 had superior progression-free (P = .045) and overall survival (P = .019). Patients who underwent AHCT2 after 2004 had superior survival (P = .026). AHCT2 is safe and feasible for disease progression after AHCT1. In this retrospective study, individuals relapsing ≥36 months from AHCT1 derived greater benefit from AHCT2 compared with those with a shorter disease-free interval. Storage of an adequate graft before AHCT1 will ensure that the option of a second autologous transplantation is retained for patients with relapsed/progressive MM.

Original languageEnglish (US)
Pages (from-to)760-766
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Cell Transplantation
Multiple Myeloma
Survival
Transplants
Recurrence
Autologous Transplantation
Disease-Free Survival
Disease Progression
Multivariate Analysis
Retrospective Studies
Transplantation
Bone Marrow
Mortality
Incidence
Therapeutics

Keywords

  • Multiple myeloma
  • Relapsed multiple myeloma
  • Second autologous transplantation

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Michaelis, L. C., Saad, A., Zhong, X., Le-Rademacher, J., Freytes, C. O., Marks, D. I., ... Hari, P. (2013). Salvage Second Hematopoietic Cell Transplantation in Myeloma. Biology of Blood and Marrow Transplantation, 19(5), 760-766. https://doi.org/10.1016/j.bbmt.2013.01.004

Salvage Second Hematopoietic Cell Transplantation in Myeloma. / Michaelis, Laura C.; Saad, Ayman; Zhong, Xiaobo; Le-Rademacher, Jennifer; Freytes, Cesar O.; Marks, David I.; Lazarus, Hillard M.; Bird, Jennifer M.; Holmberg, Leona; Kamble, Rammurti T.; Kumar, Shaji; Lill, Michael; Meehan, Kenneth R.; Saber, Wael; Schriber, Jeffrey; Tay, Jason; Vogl, Dan T.; Wirk, Baldeep; Savani, Bipin N.; Gale, Robert P.; Vesole, David H.; Schiller, Gary J.; Abidi, Muneer; Anderson, Kenneth C.; Nishihori, Taiga; Kalaycio, Matt E.; Vose, Julie M.; Moreb, Jan S.; Drobyski, William; Munker, Reinhold; Roy, Vivek; Ghobadi, Armin; Holland, H. Kent; Nath, Rajneesh; To, L. Bik; Maiolino, Angelo; Kassim, Adetola A.; Giralt, Sergio A.; Landau, Heather; Schouten, Harry C.; Maziarz, Richard; Michael, Joseph; Kindwall-Keller, Tamila; Stiff, Patrick J.; Gibson, John; Lonial, Sagar; Krishnan, Amrita; Dispenzieri, Angela; Hari, Parameswaran.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 5, 05.2013, p. 760-766.

Research output: Contribution to journalArticle

Michaelis, LC, Saad, A, Zhong, X, Le-Rademacher, J, Freytes, CO, Marks, DI, Lazarus, HM, Bird, JM, Holmberg, L, Kamble, RT, Kumar, S, Lill, M, Meehan, KR, Saber, W, Schriber, J, Tay, J, Vogl, DT, Wirk, B, Savani, BN, Gale, RP, Vesole, DH, Schiller, GJ, Abidi, M, Anderson, KC, Nishihori, T, Kalaycio, ME, Vose, JM, Moreb, JS, Drobyski, W, Munker, R, Roy, V, Ghobadi, A, Holland, HK, Nath, R, To, LB, Maiolino, A, Kassim, AA, Giralt, SA, Landau, H, Schouten, HC, Maziarz, R, Michael, J, Kindwall-Keller, T, Stiff, PJ, Gibson, J, Lonial, S, Krishnan, A, Dispenzieri, A & Hari, P 2013, 'Salvage Second Hematopoietic Cell Transplantation in Myeloma', Biology of Blood and Marrow Transplantation, vol. 19, no. 5, pp. 760-766. https://doi.org/10.1016/j.bbmt.2013.01.004
Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al. Salvage Second Hematopoietic Cell Transplantation in Myeloma. Biology of Blood and Marrow Transplantation. 2013 May;19(5):760-766. https://doi.org/10.1016/j.bbmt.2013.01.004
Michaelis, Laura C. ; Saad, Ayman ; Zhong, Xiaobo ; Le-Rademacher, Jennifer ; Freytes, Cesar O. ; Marks, David I. ; Lazarus, Hillard M. ; Bird, Jennifer M. ; Holmberg, Leona ; Kamble, Rammurti T. ; Kumar, Shaji ; Lill, Michael ; Meehan, Kenneth R. ; Saber, Wael ; Schriber, Jeffrey ; Tay, Jason ; Vogl, Dan T. ; Wirk, Baldeep ; Savani, Bipin N. ; Gale, Robert P. ; Vesole, David H. ; Schiller, Gary J. ; Abidi, Muneer ; Anderson, Kenneth C. ; Nishihori, Taiga ; Kalaycio, Matt E. ; Vose, Julie M. ; Moreb, Jan S. ; Drobyski, William ; Munker, Reinhold ; Roy, Vivek ; Ghobadi, Armin ; Holland, H. Kent ; Nath, Rajneesh ; To, L. Bik ; Maiolino, Angelo ; Kassim, Adetola A. ; Giralt, Sergio A. ; Landau, Heather ; Schouten, Harry C. ; Maziarz, Richard ; Michael, Joseph ; Kindwall-Keller, Tamila ; Stiff, Patrick J. ; Gibson, John ; Lonial, Sagar ; Krishnan, Amrita ; Dispenzieri, Angela ; Hari, Parameswaran. / Salvage Second Hematopoietic Cell Transplantation in Myeloma. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 5. pp. 760-766.
@article{c188a00d901241a1ba7e1c3ffa93b750,
title = "Salvage Second Hematopoietic Cell Transplantation in Myeloma",
abstract = "Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with multiple myeloma (MM) improves survival. However, data to support this approach for relapsed/progressive disease after initial AHCT (AHCT1) are limited. Using Center for International Blood and Marrow Transplant Research data, we report the outcomes of 187 patients who underwent a second AHCT (AHCT2) for the treatment of relapsed/progressive MM. Planned tandem AHCT was excluded. Median age at AHCT2 was 59 years (range, 28 to 72), and median patient follow-up was 47 months (range, 3 to 97). Nonrelapse mortality after AHCT2 was 2{\%} at 1 year and 4{\%} at 3 years. Median interval from AHCT1 to relapse/progression was 18 months, and median interval between transplantations was 32 months. After AHCT2, the incidence of relapse/progression at 1 and 3 years was 51{\%} and 82{\%}, respectively. At 3 years after AHCT2, progression-free survival was 13{\%}, and overall survival was 46{\%}. In multivariate analyses, those relapsing ≥36 months after AHCT1 had superior progression-free (P = .045) and overall survival (P = .019). Patients who underwent AHCT2 after 2004 had superior survival (P = .026). AHCT2 is safe and feasible for disease progression after AHCT1. In this retrospective study, individuals relapsing ≥36 months from AHCT1 derived greater benefit from AHCT2 compared with those with a shorter disease-free interval. Storage of an adequate graft before AHCT1 will ensure that the option of a second autologous transplantation is retained for patients with relapsed/progressive MM.",
keywords = "Multiple myeloma, Relapsed multiple myeloma, Second autologous transplantation",
author = "Michaelis, {Laura C.} and Ayman Saad and Xiaobo Zhong and Jennifer Le-Rademacher and Freytes, {Cesar O.} and Marks, {David I.} and Lazarus, {Hillard M.} and Bird, {Jennifer M.} and Leona Holmberg and Kamble, {Rammurti T.} and Shaji Kumar and Michael Lill and Meehan, {Kenneth R.} and Wael Saber and Jeffrey Schriber and Jason Tay and Vogl, {Dan T.} and Baldeep Wirk and Savani, {Bipin N.} and Gale, {Robert P.} and Vesole, {David H.} and Schiller, {Gary J.} and Muneer Abidi and Anderson, {Kenneth C.} and Taiga Nishihori and Kalaycio, {Matt E.} and Vose, {Julie M.} and Moreb, {Jan S.} and William Drobyski and Reinhold Munker and Vivek Roy and Armin Ghobadi and Holland, {H. Kent} and Rajneesh Nath and To, {L. Bik} and Angelo Maiolino and Kassim, {Adetola A.} and Giralt, {Sergio A.} and Heather Landau and Schouten, {Harry C.} and Richard Maziarz and Joseph Michael and Tamila Kindwall-Keller and Stiff, {Patrick J.} and John Gibson and Sagar Lonial and Amrita Krishnan and Angela Dispenzieri and Parameswaran Hari",
year = "2013",
month = "5",
doi = "10.1016/j.bbmt.2013.01.004",
language = "English (US)",
volume = "19",
pages = "760--766",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Salvage Second Hematopoietic Cell Transplantation in Myeloma

AU - Michaelis, Laura C.

AU - Saad, Ayman

AU - Zhong, Xiaobo

AU - Le-Rademacher, Jennifer

AU - Freytes, Cesar O.

AU - Marks, David I.

AU - Lazarus, Hillard M.

AU - Bird, Jennifer M.

AU - Holmberg, Leona

AU - Kamble, Rammurti T.

AU - Kumar, Shaji

AU - Lill, Michael

AU - Meehan, Kenneth R.

AU - Saber, Wael

AU - Schriber, Jeffrey

AU - Tay, Jason

AU - Vogl, Dan T.

AU - Wirk, Baldeep

AU - Savani, Bipin N.

AU - Gale, Robert P.

AU - Vesole, David H.

AU - Schiller, Gary J.

AU - Abidi, Muneer

AU - Anderson, Kenneth C.

AU - Nishihori, Taiga

AU - Kalaycio, Matt E.

AU - Vose, Julie M.

AU - Moreb, Jan S.

AU - Drobyski, William

AU - Munker, Reinhold

AU - Roy, Vivek

AU - Ghobadi, Armin

AU - Holland, H. Kent

AU - Nath, Rajneesh

AU - To, L. Bik

AU - Maiolino, Angelo

AU - Kassim, Adetola A.

AU - Giralt, Sergio A.

AU - Landau, Heather

AU - Schouten, Harry C.

AU - Maziarz, Richard

AU - Michael, Joseph

AU - Kindwall-Keller, Tamila

AU - Stiff, Patrick J.

AU - Gibson, John

AU - Lonial, Sagar

AU - Krishnan, Amrita

AU - Dispenzieri, Angela

AU - Hari, Parameswaran

PY - 2013/5

Y1 - 2013/5

N2 - Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with multiple myeloma (MM) improves survival. However, data to support this approach for relapsed/progressive disease after initial AHCT (AHCT1) are limited. Using Center for International Blood and Marrow Transplant Research data, we report the outcomes of 187 patients who underwent a second AHCT (AHCT2) for the treatment of relapsed/progressive MM. Planned tandem AHCT was excluded. Median age at AHCT2 was 59 years (range, 28 to 72), and median patient follow-up was 47 months (range, 3 to 97). Nonrelapse mortality after AHCT2 was 2% at 1 year and 4% at 3 years. Median interval from AHCT1 to relapse/progression was 18 months, and median interval between transplantations was 32 months. After AHCT2, the incidence of relapse/progression at 1 and 3 years was 51% and 82%, respectively. At 3 years after AHCT2, progression-free survival was 13%, and overall survival was 46%. In multivariate analyses, those relapsing ≥36 months after AHCT1 had superior progression-free (P = .045) and overall survival (P = .019). Patients who underwent AHCT2 after 2004 had superior survival (P = .026). AHCT2 is safe and feasible for disease progression after AHCT1. In this retrospective study, individuals relapsing ≥36 months from AHCT1 derived greater benefit from AHCT2 compared with those with a shorter disease-free interval. Storage of an adequate graft before AHCT1 will ensure that the option of a second autologous transplantation is retained for patients with relapsed/progressive MM.

AB - Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with multiple myeloma (MM) improves survival. However, data to support this approach for relapsed/progressive disease after initial AHCT (AHCT1) are limited. Using Center for International Blood and Marrow Transplant Research data, we report the outcomes of 187 patients who underwent a second AHCT (AHCT2) for the treatment of relapsed/progressive MM. Planned tandem AHCT was excluded. Median age at AHCT2 was 59 years (range, 28 to 72), and median patient follow-up was 47 months (range, 3 to 97). Nonrelapse mortality after AHCT2 was 2% at 1 year and 4% at 3 years. Median interval from AHCT1 to relapse/progression was 18 months, and median interval between transplantations was 32 months. After AHCT2, the incidence of relapse/progression at 1 and 3 years was 51% and 82%, respectively. At 3 years after AHCT2, progression-free survival was 13%, and overall survival was 46%. In multivariate analyses, those relapsing ≥36 months after AHCT1 had superior progression-free (P = .045) and overall survival (P = .019). Patients who underwent AHCT2 after 2004 had superior survival (P = .026). AHCT2 is safe and feasible for disease progression after AHCT1. In this retrospective study, individuals relapsing ≥36 months from AHCT1 derived greater benefit from AHCT2 compared with those with a shorter disease-free interval. Storage of an adequate graft before AHCT1 will ensure that the option of a second autologous transplantation is retained for patients with relapsed/progressive MM.

KW - Multiple myeloma

KW - Relapsed multiple myeloma

KW - Second autologous transplantation

UR - http://www.scopus.com/inward/record.url?scp=84876327529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876327529&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.01.004

DO - 10.1016/j.bbmt.2013.01.004

M3 - Article

VL - 19

SP - 760

EP - 766

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -